Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,581 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Sudden-Onset Clear all
Completed Not applicable Interventional

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q.3

NCT00742521
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
glucose clamp
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 17, 2026, 2:06 PM EDT
Completed No phase listed Observational

Diabetes Attitudes Wishes and Needs

NCT01507116
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Relatives to/Carers of Patients, Healthcare Professionals
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
8,985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 17, 2026, 2:06 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Liver Glycogen and Hypoglycemia in Humans

NCT03241706
View directory record Official record
Conditions
Hypoglycemia; Iatrogenic
Interventions
Low Fructose, Saline, Somatostatin, Insulin, Glucagon, Dextrose solution, High Fructose
Drug
Lead sponsor
Jason Winnick
Other
Eligibility
21 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 17, 2026, 2:06 PM EDT
Terminated Not applicable Interventional

Camp Based Multi-component Intervention for Families of Young Children With Type 1 Diabetes

NCT04279587
View directory record Official record
Conditions
Type1diabetes
Interventions
Residential camp
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 5 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 4 Interventional Results available

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

NCT01526733
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sham Injection, Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 17, 2026, 2:06 PM EDT
Active, not recruiting No phase listed Observational

MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus

NCT03945747
View directory record Official record
Conditions
Type1 Diabetes Mellitus, Diabetes Mellitus, Type 1, Autoimmune Diabetes, Juvenile Diabetes, Diabetes Mellitus Complication, Diabetic Nephropathies, Metabolic Disease, Diabetic Kidney Disease
Interventions
Blood draw, Urine sample collection, DXA scan
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 17, 2026, 2:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes

NCT03379792
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
19 Years to 30 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2

NCT00592332
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Alprazolam, control group
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes

NCT02866435
View directory record Official record
Conditions
Hypoglycemia
Interventions
Insulin, Glucose, Potassium phosphate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

NCT03216226
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
dasiglucagon, GlucaGen
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Orlando, Florida • Meridian, Idaho
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 17, 2026, 2:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Intestinal Inflammation in the Pathogenesis of Type 1 Diabetes

NCT01940835
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Upper endoscopy with small bowel biopsies and brushings., Blood draw, Stool sample
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

NCT03211858
View directory record Official record
Conditions
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Interventions
Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 1 Interventional

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

NCT05184868
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
AT247, NovoLog, Fiasp
Drug
Lead sponsor
Arecor Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 17, 2026, 2:06 PM EDT
Terminated Not applicable Interventional

Improving Metabolic Control in Diabetic Young Children

NCT00439985
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 11 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Early Phase 1 Interventional

Preventing Hypoglycemia During Exercise With Proactive Snacking on Closed Loop

NCT02135068
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Medtronic MiniMed Closed Loop (CL) System, Snacking
Device · Other
Lead sponsor
Yale University
Other
Eligibility
13 Years to 44 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 17, 2026, 2:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Investigation Into the Effects Upon Brain Response to Change in Circulating Glucose Levels in Diabetes Mellitus

NCT00580710
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Not applicable Interventional Results available

A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas

NCT02092220
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Bionic Pancreas, Insulin pump with or without CGM
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Stanford, California • Boston, Massachusetts • Worcester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Not applicable Interventional Results available

Hybrid Closed-Loop Control With Smart Prandial Insulin Dosing in Type 1 Diabetes

NCT04878120
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Standard HCL System, HCL System with Smart Bolus Calculator
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 4 Interventional

Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes

NCT00340613
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
glargine insulin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 19 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

NCT01836523
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
70
States / cities
Little Rock, Arkansas • Concord, California • Encino, California + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 17, 2026, 2:06 PM EDT
Withdrawn Phase 3 Interventional

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro

NCT04254380
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Gan & Lee Insulin Lispro Injection, Humalog
Biological
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
58
States / cities
Anaheim, California • Fresno, California • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 17, 2026, 2:06 PM EDT
Completed Not applicable Interventional

iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes

NCT02980627
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Eating Disorders
Interventions
Therapy with Mobile App Enhancement
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 17, 2026, 2:06 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D

NCT05480657
View directory record Official record
Conditions
Brittle Type 1 Diabetes Mellitus
Interventions
AT-1501 IV Infusion, Isolated cadaveric islet cells
Biological
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 17, 2026, 2:06 PM EDT
Withdrawn Phase 1 Interventional

A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus

NCT00214214
View directory record Official record
Conditions
New Onset Type 1 Diabetes Mellitus
Interventions
Campath 1H® (Alemtuzumab)
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 35 Years
Timeline
Started 2005
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 17, 2026, 2:06 PM EDT